Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

AS OF MARCH 31, 2025 AND DECEMBER 31, 2024 

(Currency expressed in United States Dollars (“US$”))

     As of      March 31,  December 31,   Note  2025  2024     (Unaudited)  (Audited) ASSETS         CURRENT ASSETS         Cash and bank balances     1,091,201   1,583,479 Fixed deposits placed with financial institutions (including $1,505,989 and $1,490,461 of fixed deposits with original maturities more than 3 months as of March 31, 2025 and December 31, 2024)     2,504,226   2,793,948 Trade receivables, net of allowance for credit losses of $537,991 and $517,877 as of March 31, 2025 and December 31, 2024 respectively (including $16,134 and $47,272 of trade receivables from related parties as of March 31, 2025 and December 31, 2024 respectively)  3   1,442,154   1,376,571 Other receivables, deposits and prepayments      235,727   203,660 Tax recoverable  4   89,937   84,167 Inventories       1,179,144   1,388,624 Total current assets      6,542,389   7,430,449              NON-CURRENT ASSETS            Operating lease right-of-use assets  5   203,923   215,243 Property, plant and equipment, net  6   1,520,279   1,522,990 Investments in equity securities  7   1,213,348   1,265,166 Total non-current assets      2,937,550   3,003,399 TOTAL ASSETS     $9,479,939   10,433,848              LIABILITIES AND STOCKHOLDERS’ EQUITY            CURRENT LIABILITIES            Trade payables